

Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies

Lucía López-Corral,¹ Luis Antonio Corchete,¹ María Eugenia Sarasquete,¹ María Victoria Mateos,¹ Ramón García-Sanz,¹ Encarna Fermiñán,² Juan-José Lahuerta,³ Joan Bladé,⁴ Albert Oriol,⁵ Ana Isabel Teruel,⁶ María Luz Martino,⁷ José Hernández,⁸ Jesús María Hernández-Rivas,¹ Francisco Javier Burguillo,⁹ Jesús F. San Miguel,¹ and Norma C. Gutiérrez¹

¹Servicio de Hematología del Hospital Universitario de Salamanca, IBSAL IBMCC (USAL-CSIC), Salamanca; ²Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca; ³Servicio de Hematología del Hospital 12 de Octubre, Madrid; ⁴Servicio de Hematología del Hospital Clinic, Barcelona; ⁵Servicio de Hematología del Hospital Germans Trias i Pujol, Badalona; ⁶Servicio de Hematología del Hospital Universitario de Valencia; ⁷Servicio de Hematología del Hospital Virgen del Rocío, Sevilla; ⁸Servicio de Hematología de Hospital General de Segovia; and ⁹Departamento de Química Física, Facultad de Farmacia, Universidad de Salamanca, Spain

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.087809

Manuscript received on July 3, 2013. Manuscript accepted on May 6, 2014.

Correspondence: lucialopezcorral@usal.es

SUPPLEMENTARY MATERIAL:

METHODS

Patients:

All the samples included in the present study were selected according to two sequential quality criteria: 1) purity > 95% for MM and SMM, and > 90% for MGUS and healthy donors; 2) at least 100 ng of high quality RNA. Since these thresholds are not easily reached in MGUS and healthy donors samples, a significant proportion of samples not fulfilling both of them were rejected. This information is provided in the table below.

Criteria	MGUS			Healthy donors		
	Total	Accepted	Rejected	Total	Accepted	Rejected
Purity > 90%	58	26	32	28	7	21
100 ng RNA (high quality)	26	20	6	7	5	2

Comparative analysis with other gene expression datasets:

In order to validate the supervised analysis of the present gene expression data, two datasets including NPC, MGUS, SMM and MM samples were generated from three series records publicly available at Gene Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo/) belonging to two different institutions: GEO GSE5900 and GSE2658 (UAMS: NPC = 22, MGUS= 44, SMM= 12 and MM= 256) and GEO GSE6477 (Mayo Clinic: NPC = 15, MGUS = 22, SMM = 24 and MM = 73).

To reduce variations caused by different Affymetrix chip versions, those probes not present in the three arrays were subtracted from the analysis based on the "U133PlusVsHuGene_BestMatch" and "hgu133_vs_hgu133_plus_best_Match" archives.

A semi-supervised approach was used to evaluate if the significant genes selected in our study were able to identify the monoclonal gammopathy groups in the two external datasets. For this purpose, a SAM multiclass analysis was made using the R/Bioconductor package siggenes (<http://www.bioconductor.org/packages/2.13/bioc/html/siggenes.html>) to select differentially expressed genes (q -values ≤ 0.001) from the 4 groups (NPC, MGUS, SMM and MM). Then, the list of genes generated by the supervised learning was used for unsupervised clustering of samples including in the UAMS and Mayo Clinic datasets.

Venn diagrams were performed with significant probesets ($q \leq 0.05$) generated from the supervised analysis applied to each dataset using the equivalent “best match” with the Human Gene 1.0 probes.

Quantitative real-time PCR validation

qRT-PCR was performed by using TaqMan gene expression assay kits (Applied Biosystems Foster City, CA, USA): Hs00559441_m1 for APAF1, Hs00171642_m1 for VCAN, Hs00391048_m1 for MEGF1, Hs03454202_s1 for TERC1, Hs03806547_s1 for TPI1, Hs00185390_m1 for BAG1, Hs00605223_g1 for RPL7A, Hs00188930_m1 for BAD, Hs03296830_s1 for SNORD55, Hs_00178289_m1 for AKT1 and Hs_99999905_m1 for GAPDH as a control gene. Relative gene expression was calculated by the $2^{-\Delta Ct}$ method, $\Delta Ct = Ct_{(gene)} - Ct_{(GAPDH)}$ (27). The Mann-Whitney U test was used to identify statistically significant differences between groups. The statistical analyses were conducted using SPSS (version 20.0; SPSS Inc., Chicago, IL, USA).

Supplementary Table S1:
Clinical and biological characteristics of the patients

Characteristics	All Patients	
MGUS (n=20)		
Sex (%)	Male / Female	68 / 32
Age (years)		78 (39-85)
Ig subtype (%)	IgG / IgA	68 / 32
Bone Marrow Plasma Cells (%)		4 (2-8)
SMM (n=33)		
Sex (%)	Male / Female	52 / 48
Age (years)		65 (39-84)
Ig subtype (%)	IgG / IgA	55 / 45
Bone Marrow Plasma Cells (%)		14 (4-48)
MM (n=41)		
Sex (%)	Male / Female	47 / 53
Age (years)		67 (41-81)
Ig subtype	IgG / IgA / BJ protein	58 / 34 / 8
ISS	I / II / III	30 / 44 / 26
Bone Marrow Plasma Cells (%)		37 (10-95)

Supplementary Table S2:
Frequency of Genetic abnormalities in MGUS, SMM and MM patients

Genetic abnormalities	MGUS (n =20)	Smoldering MM (n=33)	Symptomatic MM (n=41)	P value
	<i>Number of patients (%)</i>	<i>Number of patients (%)</i>	<i>Number of patients (%)</i>	
IgH abnormality	4/20 (20%)	11/33 (33%)	13/41 (32%)	NS
t(11;14)	1/20 (5%)	3/33 (9%)	2/41 (4.9%)	NS
t(4;14)	1/20 (5%)	3/33 (9%)	2/41 (4.9%)	NS
t(14;16)	0/20 (0%)	2/33 (6.1%)	0/10 (0%)	NS
Other	2/20 (10%)	3/33 (9%)	9/41 (22%)	NS
13q deletion	7/20 (35%)	11/33 (33%)	18/41 (44%)	NS
1q gain	10/19 (52.6%)	16/33 (48.5%)	22/40 (55%)	NS

Supplementary Table S3: Probes identifying genes exclusive of myeloid lineage

Gene Symbol	Transcript Set ID	Gene Symbol	Transcript Set ID
<i>S100A9</i>	7905571	<i>ELANE</i>	8024056
<i>MNDA</i>	7906377	<i>CEACAM8</i>	8037222
<i>CFHR1</i>	7908488	<i>BPI</i>	8062444
<i>S100A12</i>	7920238	<i>LBP</i>	8062461
<i>S100A8</i>	7920244	<i>ICOSLG</i>	8070720
<i>HBG1</i>	7937990	<i>CSTA</i>	8082058
<i>HBG2</i>	7937993	<i>LTF</i>	8086607
<i>HBB</i>	7946033	<i>HCLS1</i>	8089911
<i>HBB</i>	7946041	<i>TLR2</i>	8097903
<i>HBD</i>	7946041	<i>PF4</i>	8100966
<i>HBG1</i>	7946048	<i>PPBP</i>	8100972
<i>HBG1</i>	7946054	<i>CXCL3</i>	8100984
<i>CLEC6A</i>	7953737	<i>CXCL2</i>	8100995
<i>CLEC9A</i>	7953925	<i>CXCL14</i>	8114249
<i>LYZ</i>	7957023	<i>CD14</i>	8114612
<i>CD164</i>	7960771	<i>PILRA</i>	8134814
<i>CD163</i>	7960794	<i>LYN</i>	8146500
<i>CTSG</i>	7978351	<i>DEFA4</i>	8149109
<i>HBA1///2</i>	7991762	<i>DEFA3</i>	8149116
<i>HBA1</i>	7991766	<i>DEFA3</i>	8149126
<i>MPO</i>	8016932	<i>FCN1</i>	8165011
<i>LGALS3BP</i>	8018976	<i>AZU1</i>	8024038

Supplementary Table S4: Genes deregulated in clonal PC compared to NPC*

Probes	Gene Symbol	Score (d)			Gene Title
		MGUS vs. NPC	SMM vs. NPC	MM vs. NPC	
7902227	GADD45A	6.14	8.81	6.37	growth arrest and DNA-damage-inducible, alpha
7942824	RPS28	6.13	4.82	8.90	ribosomal protein S28
8125835	RPS10	6.05	5.33	9.11	ribosomal protein S10
8043100	TMSB10	6.00	3.97	4.66	thymosin beta 10
7990916	RPS17	5.94	6.57	6.97	ribosomal protein S17
8027024	UBA52	5.70	5.41	6.27	ubiquitin A-52 residue ribosomal protein fusion product 1
7997702	COX4I1	5.64	5.78	5.57	cytochrome c oxidase subunit IV isoform 1
8009561	RPL38	5.45	4.48	6.89	ribosomal protein L38
8125059	CLIC1	5.17	5.23	4.30	chloride intracellular channel 1
8113873	HINT1	4.94	5.38	5.87	histidine triad nucleotide binding protein 1
8122136	SNORA33	4.94	5.76	4.60	nucleolar RNA, H/ACA box 33
7908407	RPS27A	4.76	4.35	4.81	ribosomal protein S27a
7899346	CCDC72	4.66	7.66	7.52	coiled-coil domain containing 72

7902448	RPL17	4.65	4.36	5.99	ribosomal protein L17
8048195	RPL37A	4.60	5.81	5.48	ribosomal protein L37a
8078984	RPL14	4.54	4.80	4.91	ribosomal protein L14
8136039	ATP6V1F	4.47	3.96	5.56	ATPase, H ⁺ transporting, lysosomal 14kDa, V1 subunit F
8150872	RPS20	4.46	3.95	4.66	ribosomal protein S20
8076417	NDUFA6	4.44	3.87	4.65	NADH dehydrogenase (ubiquinone) 1 alpha subcomplex,
7935810	NDUFB8	4.43	4.52	5.15	NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8
8086538	LOC644714	-10.16	-6.64	-8.38	hypothetical LOC644714
8009995	UNK	-7.74	-4.56	-5.22	unkempt homolog (Drosophila)
8093456	C4orf42	-7.71	-4.47	-4.67	chromosome 4 open reading frame 42
8020495	CABLES1	-7.45	-5.34	-7.96	Cdk5 and Abl enzyme substrate 1
8018708	UBE2O	-7.03	-3.99	-5.35	ubiquitin-conjugating enzyme E2O
7982020	SNORD115-7	-6.90	-5.19	-5.24	small nuclear ribonucleoprotein polypeptide N
8079334	LIMD1	-6.82	-4.04	-4.09	LIM domains containing 1 /// hypothetical LOC644714
7967810	GOLGA3	-6.77	-4.71	-5.44	golgin A3
8026533	HSH2D	-6.71	-4.60	-5.42	hematopoietic SH2 domain containing
8081214	GPR15	-6.68	-4.76	-6.99	G protein-coupled receptor 15
8138613	OSBPL3	-6.61	-4.06	-4.61	oxysterol binding protein-like 3
8073081	APOBEC3F	-6.53	-6.83	-5.36	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F
	SNORD115-				
7982052	23	-6.43	-6.45	-6.44	small nucleolar RNA, C/D box 115-23
7982046	SNORD115-5	-6.27	-4.32	-4.31	small nucleolar RNA, C/D box 115-5
7980523	GTF2A1	-6.27	-6.19	-10.06	general transcription factor IIA, 1, 19/37kDa
	SNORD115-				
7982094	44	-6.26	-4.49	-4.49	small nucleolar RNA, C/D box 115-44
8016546	ZNF652	-6.25	-5.44	-4.80	zinc finger protein 652
	C16orf58 ///				
8001048	SLC5A2	-6.00	-4.37	-4.11	chromosome 16 open reading frame 58
8072153	CCDC117	-5.99	-5.14	-4.65	coiled-coil domain containing 117
	SNORD115-				
7982056	25	-5.97	-4.08	-4.72	small nucleolar RNA, C/D box 115-25
7965964	SLC41A2	-5.79	-5.49	-6.12	solute carrier family 41, member 2
8124459	ZNF322A	-5.76	-4.89	-5.80	zinc finger protein 322A /// zinc finger protein 322B
7982050	SNORD115-6	-5.73	-4.02	-3.93	small nucleolar RNA, C/D box 115-6 s
	SNORD115-				
7982024	24	-5.72	-4.07	-3.97	small nucleolar RNA, C/D box 115-24
7982016	SNORD115-4	-5.72	-4.07	-3.97	small nucleolar RNA, C/D box 115-4
7982028	SNORD115-3	-5.70	-4.03	-3.92	small nucleolar RNA, C/D box 115-34
7982092	SNORD115-9	-5.70	-4.03	-3.92	small nucleolar RNA, C/D box 115-9
	SNORD115-				
7982058	11	-5.70	-4.02	-3.91	small nucleolar RNA, C/D box 115-11
7918457	KCNA3	-5.69	-4.38	-6.43	potassium voltage-gated channel
8023766	RTTN	-5.65	-5.28	-5.38	rotatin
7985364	IL16 ///	-5.65	-4.13	-4.12	interleukin 16 (lymphocyte chemoattractant factor)
8043585	CIAO1	-5.64	-4.08	-4.33	cytosolic iron-sulfur protein assembly 1
	SNORD115-				
7982070	32	-5.62	-5.02	-4.71	small nucleolar RNA, C/D box 115-32
7993478	ABCC1	-5.62	-4.40	-3.96	ATP-binding cassette, sub-family C (CFTR/MRP), member 1
8014551	SYNRG	-5.62	-6.59	-7.48	synergin, gamma
	SNORD115-				
7982032	10	-5.55	-4.14	-3.91	small nucleolar RNA, C/D box 115-10
	SNORD115-				
7982008	12	-5.55	-4.14	-3.91	small nucleolar RNA, C/D box 115-12
7982038	SNORD115-	-5.55	-4.14	-3.91	small nucleolar RNA, C/D box 115-13


13					
8065444	ACSS1	-5.55	-3.93	-4.20	acyl-CoA synthetase short-chain family member 1
8065569	BCL2L1	-5.46	-5.00	-4.46	BCL2-like 1
8099721	SEL1L3	-5.44	-4.19	-5.01	sel-1 suppressor of lin-12-like 3 (<i>C. elegans</i>)
8121043	ORC3	-5.42	-4.74	-6.95	origin recognition complex, subunit 3
	LOC1005087				
7981726	97	-5.40	-10.73	-7.44	hypothetical protein LOC100508797
7998666	SNORA64	-5.31	-5.31	-4.03	ribosomal protein S2 /// small nucleolar RNA, H/ACA box 64
8099850	TMEM156	-5.20	-4.15	-5.28	transmembrane protein 156
7937802	CD81	-5.19	-3.97	-4.71	CD81 molecule
7911870	KIAA0562	-5.18	-3.98	-5.10	KIAA0562
8074931	ZNF70	-5.17	-5.30	-5.68	zinc finger protein 70
8052834	C2orf42	-5.15	-4.10	-6.01	chromosome 2 open reading frame 42
7963646	AAAS	-5.12	-4.85	-4.48	achalasia, adrenocortical insufficiency, alacrimia
8053718	IGKV2-40	-5.06	-16.12	-7.35	immunoglobulin kappa variable 2-40
8046408	PDK1	-5.05	-4.10	-4.57	pyruvate dehydrogenase kinase, isozyme 1
8004081	ZFP3	-5.01	-4.06	-5.83	zinc finger protein 3 homolog (mouse)
7993167	ATF7IP2	-5.00	-4.29	-5.54	activating transcription factor 7 interacting protein 2
7914809	KIAA0319L	-4.97	-4.07	-5.30	KIAA0319-like apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G
8073088	APOBEC3G	-4.87	-4.79	-3.94	
8022817	KLHL14	-4.85	-4.98	-4.60	kelch-like 14 (<i>Drosophila</i>)
8001746	SNORA46	-4.79	-4.80	-4.82	small nucleolar RNA, H/ACA box 46
8098556	MLF1IP	-4.75	-3.96	-5.96	MLF1 interacting protein apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D
8073072	APOBEC3D	-4.75	-4.75	-4.70	transcription elongation factor A (SII) N-terminal and central domain containing
8166096	TCEANC	-4.66	-5.04	-6.21	
7966397	ATXN2	-4.66	-4.31	-5.90	ataxin 2
8050875	ASXL2	-4.65	-5.58	-8.73	additional sex combs like 2 (<i>Drosophila</i>)
8098604	ANKRD37	-4.64	-5.56	-4.67	ankyrin repeat domain 37
8076690	C22orf9	-4.63	-5.53	-4.08	chromosome 22 open reading frame 9
8019563	MGC70870	-4.62	-4.37	-6.17	C-terminal binding protein 2 pseudogene
7900833	KDM4A	-4.59	-4.30	-4.61	lysine (K)-specific demethylase 4A
8012423	C17orf68	-4.54	-4.89	-5.72	chromosome 17 open reading frame 68
8018114	SDK2	-4.54	-4.45	-4.72	sidekick homolog 2 (chicken)
7994074	SCNN1B	-4.53	-3.95	-3.77	sodium channel, nonvoltage-gated 1, beta
7956088	RAB5B	-4.51	-5.18	-4.33	RAB5B, member RAS oncogene family
8005557	EPN2	-4.50	-4.09	-4.24	epsin 2
8153043	ZFAT	-4.47	-5.36	-4.67	zinc finger and AT hook domain containing
8065992	NFS1	-4.47	-4.18	-4.01	NFS1 nitrogen fixation 1 homolog (<i>S. cerevisiae</i>)
7930956	SEC23IP	-4.46	-4.76	-6.18	SEC23 interacting protein
8039719	ZNF606	-4.45	-4.35	-4.69	zinc finger protein 606 /// hypothetical LOC100128398
8166289	CDKL5	-4.16	-4.51	-4.72	cyclin-dependent kinase-like 5
7930614	NHLRC2	-4.05	-4.29	-5.80	NHL repeat containing 2
7899957	ZMYM4	-4.04	-4.20	-5.61	zinc finger, MYM-type 4
8086125	TRANK1	-4.02	-4.81	-5.00	tetratricopeptide repeat and ankyrin repeat containing 1
8050302	ROCK2	-4.00	-4.70	-6.42	Rho-associated, coiled-coil containing protein kinase 2
8056909	ATF2	-3.96	-4.94	-5.54	activating transcription factor 2
8036389	ZNF585B	-3.94	-4.21	-8.25	zinc finger protein 585B
7936856	CHST15	-3.90	-4.93	-5.13	carbohydrate (N-acetylgalactosamine 4-sulfate 6-O)
8073068	APOBEC3C	-3.90	-4.19	-4.12	apolipoprotein B mRNA editing enzyme
8051012	PREB	-3.90	-4.97	-4.20	prolactin regulatory element binding
8171896	CXorf21	-3.87	-4.01	-5.57	chromosome X open reading frame 21
7971422	ZC3H13	-3.84	-3.91	-5.70	zinc finger CCCH-type containing 13

7943162	C11orf54	-3.84	-4.22	-5.80	chromosome 11 open reading frame 54
8007071	CDC6	-3.84	-4.44	-4.18	cell division cycle 6 homolog (S. cerevisiae)
8103911	IRF2	-3.83	-4.70	-6.54	interferon regulatory factor 2
7930213	TAF5	-3.81	-4.77	-5.40	TAF5 RNA polymerase II,
7918487	DENND2D	-3.76	-4.34	-6.51	DENN/MADD domain containing 2D
8122807	AKAP12	-3.75	-4.13	-5.27	A kinase (PRKA) anchor protein 12
8095163	EXOC1	-3.69	-4.19	-6.29	exocyst complex component 1


*Immunoglobulin genes physiologically upregulated in NPC were eliminated

Supplementary Figure 1:

1A) Mayo Clinic dataset: Semi-supervised analysis of the 134 samples from Mayo Clinic dataset based on the 5,596 significant probes from SAM multiclass analysis of the present study dataset * $p<0.05$.




1B) UAMS dataset: Semi-supervised analysis of the 334 samples from UAMS dataset based on the 5,627 significant probes from SAM multiclass analysis of the present study dataset * $p<0.05$.




Supplementary figure 2: Comparison of expression signatures to independent monoclonal gammopathy datasets.

Venn diagram showing the number of genes commonly and specifically deregulated in the three independent datasets (Present study, Mayo Clinic and UAMS datasets) for the normal PC vs monoclonal gammopathy (clonal PC) comparison (Figure 2A) and for the MGUS vs MM comparison (Figure 2B)

2A *Normal PC versus Monoclonal Gammopathies*



2B *MGUS versus MM*



Supplementary figure 3: Expression levels of 10 genes by quantitative real-time PCR in MGUS ($n = 14$), SMM ($n = 10$) and MM ($n = 10$) patients. Relative values were calculated by the $2^{-\Delta Ct}$ method ($\Delta Ct = Ct_{(\text{gene})} - Ct_{(\text{ABL})}$). The *ABL* gene was used as control gene.

